OncoSil Medical has secured approval from the Australian Therapeutic Goods Administration for its OncoSil device to be used alongside gemcitabine-based chemotherapy for patients with unresectable locally advanced pancreatic cancer.

Patrys has taken a step toward clinical-stage development of its RLS-2202 program by appointing CMAX as the Phase 1A clinical trial site and Alithia Life Sciences as the contract research organisation to manage the study.

Cleo Diagnostics has outlined the first stage of its United States commercialisation and reimbursement plan for its Pre‑Surgical Ovarian Cancer Test as it moves toward anticipated FDA clearance.

Leaders from Australia’s medical technology sector have gathered in Perth for AusMedtech 2026 to explore innovation, translation and commercialisation across the medtech ecosystem.

AusBiotech Invest Perth 2026 will open its doors in Perth today, bringing together investors, life sciences companies, and global partners focused on the next generation of breakthroughs.

AVITA Medical has reported a cautious but positive start to 2026, with first-quarter revenue of approximately $19.3 million, up 4 per cent year over year and roughly 10 per cent sequentially, driven by contributions from Cohealyx and improving RECELL utilisation.

OncoSil Medical presented interim results from the OSPREY Registry at ESGE Days 2026, reporting encouraging real-world safety and efficacy outcomes for patients with unresectable locally advanced pancreatic cancer treated with EUS-guided phosphorus-32 microparticles.

Racura Oncology has received clearance from its Safety Review Committee to escalate the RC220 dose in the Phase 1 CPACS trial following a review of safety and pharmacokinetic data from the first cohort.

AusBiotech says the 2026-27 Federal Budget sends strong signals that the Government has listened to its advocacy, but the peak life sciences body is urging careful scrutiny of the tax changes to understand their true impact.

AusBiotech has launched the latest edition of the Australasian Biotechnology Journal ahead of AusMedtech 2026, bringing together perspectives from across Australia’s life sciences ecosystem.

The study is part of Neurizon’s broader NUZ-001 program and runs alongside the company’s participation in the Phase 2/3 HEALEY ALS Platform Trial in the United States. 

Nexsen has taken a significant step into Asia by signing a binding term sheet with GHK Hospital, a subsidiary of IHH Healthcare Berhad, to create a strategic collaboration for clinical validation, real-world data generation and commercialisation of its rapid point-of-care diagnostic platform.

Control Bionics has announced that Professor Nicholas Opie has joined the company as a Non-Executive Director and strategic advisor, a move the board says will sharpen the business as it advances its neuroelectric signal platform.

Gordon Naylor, who stepped into CSL's interim chief executive role in February, has completed a 90-day review and set out a plan to accelerate the company’s transformation.

BCAL Diagnostics has announced the appointment of Anne Louise Arnett as Chief Executive Officer, effective 1 June 2026, as the company accelerates the commercial rollout of its early cancer detection products.

Amplia Therapeutics and the Australia New Zealand Gynaecological Oncology Group have launched a new investigator-initiated clinical study to test the FAK inhibitor narmafotinib in combination with standard chemotherapy.

Neurizon Therapeutics has appointed a new Chief Financial Officer to strengthen its leadership as it prepares to advance its lead drug candidate, NUZ 001, through late-stage clinical trials and to build readiness for future commercialisation.